Notice of Extension for RFA-TR-25-002 Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)

About this opportunity

National Center for Advancing Translational Sciences (NCATS) The purpose of this Notice is to inform applicants that effective immediately the National Center for Advancing Translational Sciences (NCATS) is extending RFA-TR-25-002 "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" by one Council round. The following text in bold and italics has been updated to reflect the extension: Office of Drug Development Partnership ProgramsEmail: [email protected]